A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors

Clinical trial NCT05892718 · RECRUITING

Trial details

NCT number: NCT05892718
Sponsor: FBD Biologics Limited
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor Refractory Non-Hodgkin Lymphoma

Start date: 2023-10-02
Primary completion: 2027-05-30
Enrollment: 80

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.